ClinicalTrials.gg
CompletedNCT00831974Updated Dec 11, 2018

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

A Phase 2 interventional study of masitinib (AB1010) and masitinib (AB1010) in Mastocytosis, sponsored by AB Science. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-11.

Sponsored by AB Science · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a 12 weeks study aimed at assessing the safety and efficacy of 2 doses of AB1010 in patients suffering from indolent systemic mastocytosis with handicap.

Read the detailed description

Efficacy will be assessed based on:

Pruritus score Number of flush per day Pollakyuria (on a daily basis) Number of stools per day QLQ-C30 score Hamilton Rating Scale for depression

02

Conditions studied

  • Mastocytosis

Browse trials for

Keywords

  • mastocytosis
  • indolent
  • handicap
  • wild-type
  • systemic
  • not D816V mutated
03

In context

Mastocytosis

49 studies on the registry are indexed under Mastocytosis; 14 are open to participants now.

This study's enrollment of 23 is below the median of 30 across 23 interventional studies indexed under Mastocytosis.

Browse Mastocytosis studies →

Lead sponsor

AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with documented Indolent systemic mastocytosis with handicap (ISMwh) having at least 2 infiltrated* organs (skin and /or bone-marrow and/or internal organ).
  2. Bone-marrow, or skin or internal -documented mastocytosis and evaluable disease.
  3. The absence of an activating point mutation in the phosphotransferase domain of c-Kit such as D816V c-Kit mutation in at least one of the two infiltrated organs: bone marrow and/or skin and/or other tissue.
  4. Handicap defined as at least one of the following handicaps:

    • a number of flush per day ≥ 1 ,
    • a pruritus score ≥ 9 ,
    • a number of stools per day ≥ 4 ,
    • a Pollakyuria (on a per day basis) ≥ 8 ,
    • a QLQ-C30 score ≥ 83 ,
    • a Hamilton rating scale for depression ≥ 12

Exclusion criteria

Exclusion Criteria:

  1. Performance status > 2 ().
  2. Inadequate organ function, except if the abnormalities are due to involvement by mast cells
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    2

    masitinib (AB1010) 6 mg/kg/day

    Drug: masitinib (AB1010)

  • Experimental
    1

    masitinib (AB1010) 3 mg/kg/day

    Drug: masitinib (AB1010)

Interventions

06

What researchers measure

Primary outcomes

  1. Response on: Pruritus score, Number of flush per day, Pollakyuria (on a daily basis), Number of stools per day, QLQ-C30 score, Hamilton Rating Scale for depression

    Time frame: 12 weeks

Secondary outcomes

  1. AFIRMM score, reduction of organ infiltration,level of tryptase, reduction on bio markers (TNFα, eosinophils, histamine levels), pharmacokinetic profile of AB1010

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmerini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010 Dec;85(12):921-5. doi: 10.1002/ajh.21894. PubMed 21108325 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004 and a primary completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2009
First posted
Jan 29, 2009
Start
Oct 2004
Primary completionActual
Feb 2007
Last update
Dec 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00831974
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jan 29, 2009
Start date
Oct 2004
Primary completion
Feb 2007
Last update
Dec 11, 2018

Study contacts

Olivier Lortholary, MD, PhD
principal investigator · Hôpital Necker, Paris, France

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion